Cellect Biomed Ltd.

General Information
Business:

(Note – public offering: “Our ordinary shares are currently traded on the Tel Aviv Stock Exchange, or the TASE, under the symbol “CLBD” (since 1990).”

We are an emerging biotechnology company that has developed a novel technology platform known as Powered by Cellect that functionally selects stem cells in order to improve the safety and efficacy of regenerative medicine stem cell therapies. We aim to become the standard enabling technology for the enrichment of the stem cell population for companies developing stem cell therapies, physicians practicing regenerative medicine and for researchers and academia engaged in stem cell research.

Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Employees: 14
Founded: 1986
Contact Information
Address 23 Hata’as Street, Kfar Saba, Israel 44425
Phone Number (+972) (9) 974 1444
Web Address http://www.cellectbio.com
View Prospectus: Cellect Biomed Ltd.
Financial Information
Market Cap
Revenues $0.0 mil (last 12 months)
Net Income $-3.1 mil (last 12 months)
IPO Profile
Symbol APOP
Exchange NASDAQ
Shares (millions): 1.4
Price range $0.00 - $0.00
Est. $ Volume $10.0 mil
Manager / Joint Managers Rodman & Renshaw (a unit of H.C. Wainwright & Co.)
CO-Managers Chardan Capital Markets
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change